FDA Approves Home-Use Antibody Form for Alzheimer's Treatment
The FDA has approved a form of antibody treatment targeting the biological process of Alzheimer's patients that can be administered at home via an auto-injector device. The treatment, which is not yet licensed in Turkey, aims to slow the rate of disease progression.
The US Food and Drug Administration (FDA) has approved the subcutaneous injection form of an antibody treatment aimed at slowing the progression of Alzheimer's disease, which can be administered at home. Prof. Dr. Evlice, President of the Alzheimer's Association of Turkey Adana Branch, stated that this new method, approved in July 2026, will reduce hospital visits, but the drug is not yet licensed in Turkey.
Era of Home Treatment
An auto-injector device form administered subcutaneously has been developed for antibody treatment targeting the biological process in Alzheimer's treatment. Approved by the US Food and Drug Administration (FDA) in July 2026, this form allows the treatment process to be continued at home by the patient or a caregiver in eligible patients.
Situation in Turkey and Purpose of Treatment
Making statements within the scope of September 21 World Alzheimer's Day, Prof. Dr. Evlice, President of the Alzheimer's Association of Turkey Adana Branch, announced that this newly approved treatment form is not yet licensed in Turkey. Prof. Dr. Evlice emphasized that the purpose of the treatment is not to completely eliminate the disease, but to reduce the rate of progression.
Stating that clinical studies show that antibody treatments started in the early period can slow down cognitive and functional decline, Evlice expressed that the home administration method will significantly reduce the burden of hospital visits.
Risks and Follow-up Process
Reminding that the new method is not a completely risk-free treatment, experts point out that making the right patient selection and performing brain MRI follow-ups during the treatment process are of great importance.